Fact.MR projects that the global market for paronychia treatments will reach US$ 1 billion by 2033, growing at a 7.1% CAGR between 2023 and 2033.

Diabetes is becoming increasingly frequent in many parts of the world, which is expected to fuel market growth. Diabetic patients are at a higher risk of developing paronychia; thus, a rise in the prevalence of diabetes around the world can lead to an increase in paronychia disease. Moreover, it takes longer for diabetic patients to recover from paronychia than non-diabetic patients.

The bourgeoning geriatric population globally is major factor projected to drive the demand for paronychia treatment. The immune system’s functionality gradually declines with age. As a result, cognitive and physical changes in the elderly make them more vulnerable to diseases such as paronychia.

Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8469?AS 

Chronic paronychia develops gradually and may stay for several weeks. In such circumstances, the infection is caused by a confluence of microorganisms. A virus, such as herpes simplex, yeast like candida, and bacteria, such as Staphylococcus aureus, can be found in chronic paronychia.

Key Highlights

  • The global paronychia treatment market amounted to US$ 500 million in 2023.
  • Worldwide demand for paronychia treatment is estimated to swell at a CAGR of 7.1% during the forecast period (2023 to 2033).
  • The paronychia treatment market is set to reach US$ 1 billion by 2033.
  • North America is ruling the global paronychia treatment market.

“Growing elderly population and increasing prevalence of diabetes globally are the main factors expected to drive the global paronychia treatment market. Moreover, key market players are strongly focusing on research and development activities to develop new therapies for paronychia,” says a Fact.MR analyst.

Key players in the paronychia treatment market are constantly focusing on developing new items to gain a global market share. As a result, these players are increasing their investment in research and development to lead the worldwide market.

Many market players are focused more on collaboration and acquisition to expand their product portfolios, allowing them to boost their presence in the worldwide market and gain the most share.  Start-ups operating in the global market are also concentrating on developing innovative products.

  • The US Food and Drug Administration approved Bausch Health’s Jublia in April 2021. Jublia is a topical solution used to treat paronychia in patients aged six and up.
  • Mundipharma struck a new agreement in November 2020 with Moberg Pharma to market its consumer healthcare product for treating nail disorders throughout the Middle East & Africa (MEA). The company specializes in topical therapy for nail and skin disorders.

Market Titans

  • Glenmark Generics Ltd
  • GlaxoSmithKline plc
  • Eli Lilly Company
  • Teva Pharmaceutical Industries Ltd
  • Fougera Pharmaceuticals Inc
  • Jonakayem Pharma Formulation

Regional Analysis

North America is leading the global paronychia treatment market. The United States is witnessing substantial growth due to the increasing prevalence of chronic and acute paronychia. Asia Pacific is also experiencing considerable growth in the worldwide market due to the expanding elderly population in South Korea and Japan. Furthermore, Germany and the United Kingdom are significantly contributing to the regional market due to strong investments in healthcare.

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global paronychia treatment market, presenting forecast statistics for the period (2023 to 2033).

The study divulges essential insights on the market based on type (acute paronychia, chronic paronychia), product (mupirocin ointment, fusidic acid ointment, gentamicin ointment, dicloxacillin), and end user (hospitals & clinics, dermatology centers), across five major regions of the world (North America, Europe, Asia Pacific, Latin America)

Contact:
US sales Office :
marketoutlook0 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: [email protected]